Tumor characteristics and clinical outcomes in head and neck squamous cell carcinoma: a retrospective analysis of 40 patients in Baghdad, Iraq
Main Article Content
Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) shows wide variation in clinical behavior and outcome, and regional risk factors contribute to that variation. Local clinicopathological data are therefore needed before management strategies can be matched to the population being served. Aims: To analyze tumor characteristics, staging patterns, treatment modalities, and survival outcomes in a cohort of HNSCC patients from Baghdad, Iraq. Methods: We conducted a retrospective analysis of 40 HNSCC patients diagnosed between 2018-2022. Comprehensive data collection included demographics, tumor characteristics, TNM staging (AJCC 8th ed.), histopathological features, treatment modalities, and survival outcomes. Statistical analysis was performed using Kaplan-Meier survival curves, logistic regression, and correlation analysis. Results: The mean patient age was 62.98 years (range: 43-85), with a male predominance (80%). Laryngeal tumors were most prevalent (42.5%). Patients typically presented with large tumors (mean size: 6.94 cm) and aggressive histopathological features, including high rates of lymphovascular invasion (77.5%) and perineural invasion (47.5%). Advanced disease (Stage IV) was present in 50% of cases at diagnosis. Combined multimodal therapy was the most common treatment approach (57.1%). Survival showed a strong negative correlation with tumor stage (p < 0.0001), with Stage IV patients having a median survival of 0.67 years compared to over 4 years for early-stage disease. Conclusion: HNSCC in this Baghdad-based series was usually diagnosed late and showed biologically aggressive features, with correspondingly poor survival. Stage at diagnosis was the dominant prognostic factor. Earlier detection and locally relevant public-health measures targeting the risk profile of the region are needed.
Received date: 02-06-2025
Accepted date: 17-09-2025
Published date: 15-06-2026
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licenses and Copyright
The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.
# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner. If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.
# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but that’s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.
# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.
# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.
How to Cite
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of in-cidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74:229-263. DOI: https://doi.org/10.3322/caac.21834
Johnson DE, Burtness B, Leemans CR, Lui VW, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Pri-mers. 2020; 6:92. DOI: https://doi.org/10.1038/s41572-020-00224-3
Alsahafi E, Begg K, Amelio I, Raulf N, Lucarelli P, Sauter T, et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis. 2019; 10:540. DOI: https://doi.org/10.1038/s41419-019-1769-9
Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67:122-137. DOI: https://doi.org/10.3322/caac.21389
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72:7-33. DOI: https://doi.org/10.3322/caac.21708
Alsanosy RM. Smokeless tobacco (shammah) in Saudi Arabia: a review of its pattern of use, prevalence, and potential role in oral cancer. Asian Pac J Cancer Prev. 2014; 15:6477-6483. DOI: https://doi.org/10.7314/APJCP.2014.15.16.6477
Akl EA, Gaddam S, Gunukula SK, Honeine R, Jaoude PA, Irani J. The effects of waterpipe tobacco smoking on health outcomes: a systematic review. Int J Epidemiol. 2010; 39:834-857. DOI: https://doi.org/10.1093/ije/dyq002
Choi SH, Terrell JE, Fowler KE, McLean SA, Ghanem T, Wolf GT, et al. Socioeconomic and other demographic disparities predicting survival among head and neck cancer patients. PLoS One. 2016; 11:e0149886. DOI: https://doi.org/10.1371/journal.pone.0149886
Zanoni DK, Patel SG, Shah JP. Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications. Curr Oncol Rep. 2019; 21:52. DOI: https://doi.org/10.1007/s11912-019-0799-x
Sankaranarayanan R, Ramadas K, Thara S, Muwonge R, Thomas G, Anju G, et al. Long term effect of visual screening on oral cancer incidence and mortality in a randomized trial in Kerala, India. Oral Oncol. 2013; 49:314-321. DOI: https://doi.org/10.1016/j.oraloncology.2012.11.004
Halboub ES, Abdulhuq M, Al-Mandili A. Oral and pharyngeal cancers in Yemen: a retrospective study. East Mediterr Health J. 2012; 18:985-991. DOI: https://doi.org/10.26719/2012.18.9.985
Museedi OS. Oral cancer awareness among group of general dental practitioners in Iraq. J Bagh Coll Dent. 2014; 26:108-111. DOI: https://doi.org/10.12816/0015174
Schmitd LB, Scanlon CS, D’Silva NJ. Perineural invasion in head and neck cancer. J Dent Res. 2018; 97:742-750. DOI: https://doi.org/10.1177/0022034518756297
Jardim JF, Francisco ALN, Gondak R, Damascena A, Kowalski LP. Prognostic impact of perineural invasion and lymphovascular invasion in advanced stage oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2015; 44:23-28. DOI: https://doi.org/10.1016/j.ijom.2014.10.006
Mohammed AK, Al-Drobie B, Abdullah BH. Perineural invasion in salivary gland carcinomas in relation to tumor grade and histo-logical subtypes. J Med Chem Sci. 2023; 6:1469-1486.
Rasheed FS, Abdullah BH, Museedi OS, Hussein WA. Estimating the Role of Neurotrophins in Perineural Invasion in Oral Squa-mous Cell Carcinoma. Int Med J. 2021; 28:40-42.
López-Ozuna VM, Gupta I, Liu Chen Kiow R, Matanes E, Kheraldine H, Yasmeen A, et al. Water-pipe smoking exposure deregulates a set of genes associated with human head and neck cancer development and prognosis. Toxics. 2020; 8:73. DOI: https://doi.org/10.3390/toxics8030073
Zanoni DK, Montero PH, Migliacci JC, Shah JP, Wong RJ, Ganly I, et al. Survival outcomes after treatment of cancer of the oral cavity (1985-2015). Oral Oncol. 2019; 90:115-121. DOI: https://doi.org/10.1016/j.oraloncology.2019.02.001
Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020; 18:873-898. DOI: https://doi.org/10.6004/jnccn.2020.0031
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349:2091-2098. DOI: https://doi.org/10.1056/NEJMoa031317
Soulières D, de Castro G, Psyrri A, Basté N, Neupane P, Fuereder T, et al. Pembrolizumab alone or with chemotherapy versus ce-tuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a random-ised, open-label, phase 3 study. Lancet. 2019; 394:1915-1928. DOI: https://doi.org/10.1016/S0140-6736(19)32591-7
Ferris RL, Blumenschein Jr G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375:1856-1867. DOI: https://doi.org/10.1056/NEJMoa1602252
Abdulla BH, Jubair KK, Younis WH. A Comparative Study of Immunohistochemical Expression of Moesin, Cytokeratin 14 and MMP7 in Oral Squamous Cell Carcinoma and Oral Verrucous Carcinoma. J Bagh Coll Dent. 2016; 28:52-58. DOI: https://doi.org/10.12816/0028234